NasdaqGM - Delayed Quote USD
Protagonist Therapeutics, Inc. (PTGX)
44.41
+0.64
+(1.46%)
At close: May 15 at 4:00:00 PM EDT
42.01
-2.40
(-5.40%)
Pre-Market: 4:01:25 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -0.5 | -0.53 | -1.41 | -1.14 |
| Low Estimate | -0.68 | -0.72 | -2.34 | -3.71 |
| High Estimate | -0.09 | -0.3 | -0.29 | 2.75 |
| Year Ago EPS | -0.5 | -0.54 | 4.3 | -1.41 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 10 | 10 |
| Avg. Estimate | 7.41M | 7.54M | 92.5M | 183.81M |
| Low Estimate | -- | -- | 28.3M | -- |
| High Estimate | 28.3M | 28.3M | 253.4M | 525M |
| Year Ago Sales | 4.17M | 4.67M | 434.43M | 92.5M |
| Sales Growth (year/est) | 77.89% | 61.23% | -78.71% | 98.72% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.41 | -0.53 | 0.25 | 0.11 |
| EPS Actual | -0.5 | -0.54 | 1.98 | -0.19 |
| Difference | -0.09 | -0.01 | 1.73 | -0.3 |
| Surprise % | -21.11% | -1.89% | 692.00% | -272.73% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.5 | -0.53 | -1.41 | -1.14 |
| 7 Days Ago | -0.53 | -0.51 | -1.23 | -1.07 |
| 30 Days Ago | -0.53 | -0.51 | -1.23 | -1.07 |
| 60 Days Ago | -0.53 | -0.51 | -1.24 | -1.08 |
| 90 Days Ago | -0.53 | -0.58 | -0.83 | -0.98 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | -- | 5 | 2 |
| Up Last 30 Days | 3 | -- | 5 | 2 |
| Down Last 7 Days | 4 | 5 | 2 | 5 |
| Down Last 30 Days | 4 | 5 | 2 | 5 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PTGX | -0.86% | 1.32% | -132.86% | 19.56% |
| S&P 500 | 13.17% | 2.85% | 7.92% | 13.78% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/10/2025 |
| Reiterates | Wedbush: Outperform to Outperform | 3/28/2025 |
| Maintains | Truist Securities: Buy to Buy | 3/11/2025 |
| Reiterates | BMO Capital: Outperform to Outperform | 3/11/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2025 |
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 3/10/2025 |
Related Tickers
MLTX MoonLake Immunotherapeutics
37.66
+1.81%
CRNX Crinetics Pharmaceuticals, Inc.
31.21
-0.26%
RYTM Rhythm Pharmaceuticals, Inc.
60.18
+5.06%
SRRK Scholar Rock Holding Corporation
30.83
+0.95%
AKRO Akero Therapeutics, Inc.
39.96
+5.49%
CYTK Cytokinetics, Incorporated
29.84
-0.53%
IDYA IDEAYA Biosciences, Inc.
17.31
+1.23%
BBIO BridgeBio Pharma, Inc.
33.74
+0.24%
KYMR Kymera Therapeutics, Inc.
30.02
+0.91%
ACLX Arcellx, Inc.
58.45
-0.97%